A new electronic health record (EHR)-based marker may help doctors identify transplant patients who face a high risk of organ rejection before serious complications develop. Researchers found that a simple measurement derived from routine laboratory tests can pinpoint patients who struggle to take their medications consistently.
The discovery could transform transplant care by enabling physicians to intervene earlier and prevent rejection rather than reacting after damage occurs.
The Challenge of Medication Nonadherence
Medication adherence remains one of the biggest challenges in organ transplantation. Patients must take immunosuppressive drugs regularly to prevent their immune systems from attacking the transplanted organ. However, many patients, especially adolescents and young adults, struggle to follow these strict medication schedules.
As a result, missed doses often lead to organ rejection, hospitalizations, and even the need for another transplant. Unfortunately, clinicians have lacked reliable methods to detect medication nonadherence before complications arise.
Why Early Detection Matters
Doctors traditionally rely on patient self-reporting or intensive monitoring programs to identify adherence problems. However, these approaches have limitations. Patients may not accurately report their medication habits, and extensive monitoring requires significant healthcare resources.
Therefore, researchers have been searching for objective and scalable solutions that can identify at-risk patients early.
What Is the Medication Level Variability Index (MLVI)?
The new marker, called the Medication Level Variability Index (MLVI), uses information already available in electronic health records. It analyzes fluctuations in blood levels of immunosuppressive medications to detect inconsistent medication use.
Because transplant patients undergo routine blood tests, physicians can calculate MLVI without adding extra procedures or costs. The approach makes use of existing clinical data and provides an objective measure of adherence risk.
A Simpler Alternative to Traditional Monitoring
Unlike invasive biopsies or specialized testing, MLVI depends on standard laboratory values. Researchers believe this simplicity could accelerate adoption across transplant centers.
In addition, emerging evidence shows that biomarkers and EHR-based indicators can improve transplant monitoring and help physicians identify rejection risks earlier than conventional methods.
Landmark Multicenter Study Validates the Approach
Researchers from the Icahn School of Medicine at Mount Sinai led a large multicenter trial involving 13 pediatric transplant centers across the United States and Canada.
The team screened more than 3,000 health records from liver transplant recipients. They identified 148 adolescents and young adults with high MLVI scores, indicating a greater risk of medication nonadherence and organ rejection.
Participants were randomly assigned to receive either standard care or a two-year remote behavioral intervention designed to improve medication adherence.
Promising Clinical Outcomes
Although the trial did not achieve statistical significance for its primary endpoint, the findings remained encouraging.
Patients receiving the intervention experienced approximately half as many rejection-related events and re-transplantations compared with those receiving standard care. Moreover, transplant centers that routinely used MLVI reported rejection rates similar to those seen in traditionally low-risk patients.
Remote Interventions Show Strong Potential
The study also demonstrated the effectiveness of telehealth-based behavioral interventions. Healthcare specialists regularly connected with patients remotely to encourage medication adherence and provide ongoing support.
Importantly, the program maintained patient engagement throughout the COVID-19 pandemic. Researchers successfully enrolled new participants and continued monitoring existing patients despite widespread healthcare disruptions.
Benefits Beyond Liver Transplants
Experts believe the findings could extend beyond pediatric liver transplantation. Similar EHR-based approaches may benefit patients with kidney, heart, and lung transplants, where medication adherence remains a persistent challenge.
Furthermore, transplant medicine increasingly relies on biomarkers and digital tools to predict rejection risks earlier and personalize patient care. Researchers continue to explore blood-based, urine-based, and molecular markers that can complement traditional monitoring methods.
The Future of Transplant Care
The introduction of MLVI marks an important shift in transplant medicine. Instead of waiting for signs of rejection, clinicians can identify vulnerable patients sooner and provide targeted interventions.
This proactive approach could reduce hospitalizations, lower healthcare costs, and improve long-term transplant success rates. Additionally, it may help healthcare systems allocate resources more effectively by focusing support on patients who need it most.
From Reaction to Prevention
Researchers emphasize that more studies are needed to refine intervention strategies and determine the most cost-effective care models. Nevertheless, the evidence strongly supports integrating MLVI into routine clinical practice.
By moving from reactive care to preventive care, transplant teams may significantly improve patient outcomes and extend the life of transplanted organs.
Conclusion
Electronic health records are becoming powerful tools in modern healthcare. The Medication Level Variability Index demonstrates how existing patient data can reveal hidden risks and guide earlier interventions.
As transplant medicine evolves, EHR-based markers like MLVI may help physicians prevent organ rejection, personalize treatment plans, and improve the quality of life for thousands of transplant recipients worldwide.
